A treatment strategy for KRAS-driven tumors
Nat Med
.
2018 Jul;24(7):902-904.
doi: 10.1038/s41591-018-0111-x.
Authors
Trang T Mai
1
,
Piro Lito
2
3
Affiliations
1
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. litop@mskcc.org.
3
Weill Cornell Medical College, Cornell University, New York, NY, USA. litop@mskcc.org.
PMID:
29988139
DOI:
10.1038/s41591-018-0111-x
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Humans
Lung Neoplasms*
Proto-Oncogene Proteins p21(ras)*
Substances
KRAS protein, human
Proto-Oncogene Proteins p21(ras)
Grants and funding
R01 CA230745/CA/NCI NIH HHS/United States